SCP
TEVA icon

Sender Company & Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Sender Company & Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-129,612
Closed -$2.62M – 415
2025
Q3 		$2.62M Sell
129,612
-41,546
-24% -$730K 0.29% 92
2025
Q2 		$2.87M Buy
+171,158
New +$2.76M 0.81% 28

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Sender Company & Partners's TEVA Position: Q4 2025 in Review

Sender Company & Partners sold out of Teva Pharmaceuticals (TEVA) in Q4 2025, closing a stake of 129,612 shares — an estimated $2.62M sold.

Sender Company & Partners first reported a position in TEVA in Q2 2025 and held it in 2 quarters. The position peaked at $2.87M in Q2 2025. 631 funds tracked by Wall St. Rank hold TEVA as of Q4 2025.

  • Sender Company & Partners reported no remaining Teva Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Sender Company & Partners sold 129,612 Teva Pharmaceuticals shares in Q4 2025, an estimated $2.62M.
  • Sender Company & Partners first reported a position in Teva Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Sender Company & Partners's Teva Pharmaceuticals position peaked at $2.87M in Q2 2025.
  • 631 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2025.

Based on Sender Company & Partners's 13F filing for Q4 2025, filed 17 Feb 2026.